Fmoc-Cys-OMe (3)
4.15 g (30 mmol, 3 eq.) of K 2 CO 3 were added to a solution of Fmoc-cys(Trt)-OH 1 (5.86 g, 10.0 mmol, 1 eq.) in 30 mL of DMF under N 2 . The solution was stirred at room temperature for 15 min. Then, 1.90 mL of MeI (4.26 g, 30 mmol, 3 eq.) were added and the mixture was stirred for an additional 3 hrs. The reaction was diluted with 30 mL of H 2 O and extracted with 50 mL of EtOAc. The organic layer was then washed with brine (3 x 20 mL) and a saturated aqueous solution of Na 2 SO 3 (2 x 15 mL), dried with sodium sulphate and concentrated under vacuum. The crude product was immediately used in the next reaction in which it was redissolved in 500 mL of DCM and 20 mL of TIS were added followed by the addition of 40 mL of TFA. The reaction was stirred for 30 minutes at r.t. after which the solvent was evaporated under vacuum. Remaining TFA was co-evaporated with Et 2 O. The obtained white powder was transferred to falcon tubes and washed 5 times with 40 mL of hexane. Product 3 was obtained as a white powder in 82% yield over two steps (2.93 g, 8 .20 mmol).
ESI -
4.44 (dd, J = 7.0, 3.6 Hz, 2H), 4.24 (t, J = 6.9 Hz, 1H), 3 .01 (t, J = 7.8, 3.6 Hz, 2H), 1.36 (t, J = 8.9 Hz, 1H). 13 
Synthesis of (2-bromoethyl) trimethyl phosphonium bromide (4)
P + Br Br -
4
A solution of trimethyl phosphine (2.00 mL, 20.0 mmol, 1 eq.) in 100 mL of CH 3 CN was added dropwise to a solution of 1,2-dibromoethane (34.4 mL, 400 mmol, 20 eq.) in 200 mL of CH 3 CN. After addition, the mixture was stirred at r.t. for 3 days under N 2 . The solvent was evaporated under vacuum and the white solid was washed with Et 2 O to remove excess of 1,2-dibromoethane. Product 4 was obtained as a white solid in 63% yield (3.37 g, 12.76 mmol).
1 H NMR (400 MHz, MeOD) δ 3.77 (dt, J = 13.8, 7.6 Hz, 2H), 3 .00 (dt, J = 14.0, 7.6 Hz, 2H), 2.00 (d, J = 14.7 Hz, 9H). 13 C NMR (101 MHz, MeOD) δ 28.6, 28.1, 22.9, 22.8, 8.8, 8.2.
31 P NMR (162 MHz, MeOD) δ 27.8. 
Synthesis of (3-bromopropyl) trimethyl phosphonium bromide (5)
P
5
A solution of containing trimethyl phosphine (0.74 mL, 7.43 mmol, 1 eq.) in 50 mL of CH 3 CN was added dropwise to a solution of 1,3-dibromopropane (15.08g, 148.6 mmol, 20 eq.) in 150 mL of CH 3 CN. After the addition, the mixture was stirred under N 2 for 3 days at r.t.. The solvent was evaporated under vacuum and the obtained white solid was washed with Et 2 O to remove excess of 1,3-dibromopropane. Product 5 was obtained as a white solid in 80% yield (1.65 g, 5.95 mmol).
1 H NMR (400 MHz, MeOD) δ 3.60 (t, J = 6.3 Hz, 2H), 2.52 -2.39 (m, 2H), 2.23 -2.11 (m, 2H), 1.95 (d, J = 14.6 Hz, 9H). 13 C NMR (101 MHz, MeOD) δ 32.3, 32.1, 24.6, 24.5, 22.2, 21.7, 7.0, 6.4. 31 P NMR (162 MHz, MeOD) δ 27.7. 3.43 g of the Fmoc-Cys-OH 2 (10.0 mmol, 1 eq), 2.64 g of (2-bromoethyl)-trimethyl phosphonium bromide 4 (10.0 mmol, 1 eq) and 1.58 g of NaHCO 3 (20.0 mmol, 2 eq) were dissolved in 20 mL of a THF:H 2 O mixture (9:1 v/v), that was previously degassed in a sonicator. The reaction mixture was stirred and heated to reflux overnight under a N 2 atmosphere, after which the reaction mixture was acidified with concentrated HCl. The reaction mixture was concentrated in vacuo and the residue re dissolved in Acetone. The formed NaCl was filtrated and the solvent was evaporated in vacuo. The resulting product was purified by reverse phase column chromatography using H 1.79 g of the Fmoc-Cys-OMe 3 (5 mmol, 1 eq), 1.39 g of (3-bromopropyl)-trimethyl phosphonium bromide 5 (5 mmol, 1 eq) and 0.84 g of NaHCO 3 (10 mmol, 2 eq) were dissolved in 50 mL of a mixture THF:H 2 O (9:1 v/v) that was previously degassed in a sonicator. The reaction mixture was stirred and heated to reflux temperature overnight under a N 2 atmosphere, after which reaction mixture was acidified with concentrated HCl and the mixture was stirred for other 72 hrs. The reaction mixture was concentrated in vacuo and the residue re dissolved in Acetone. The formed NaCl was filtrated and the solvent was evaporated in vacuo. The resulting product was purified by reverse phase column chromatography using H 2 O:CH 3 CN (95:5) -CH 3 CN:H 2 O (95:5) as eluent system in a 0%-80% gradient. Fractions containing pure phosphonium salt 6 were collected, lyophilized and the product was obtained as a white solid in an 65% yield over two steps (1.66 g, 3.26 mmol) 1 H NMR (400 MHz, MeOD) δ 7.80 (d, J = 7.5 Hz, 2H), 7.68 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7. Fmoc-Rink-Amide AM resin (500 mg, 0.115 mmol; 0.23 mmol/g, 1 eq.) in a polypropylene syringe containing a polyethylene frit, was washed with 4 mL of DMF (5 × 1 min), 4 mL of DCM (5 × 1 min) and 4 mL of DMF (5 × 1 min). Deprotection of the Fmoc group was achieved by treatment of the resin with 4 mL of 20% PIP/DMF (1 × 1 min and 2 × 5 min) followed by washing with 4 mL of DMF (5 × 1 min), 4 mL of DCM (5 × 1 min) and 4 mL of DMF (5 × 1 min). The protected Fmoc-amino acids (4 eq. for the natural amino acids, 2 eq. for the phosphonium amino acids), were incorporated using DIC (4 eq. and 2 eq. respectively) and Oxyma (4 eq. and 2 eq. respectively) in 4 mL of DMF, as a coupling system with 5 min pre-activation, for 1 hr (normal) or overnight (phosphonium amino acids) couplings at r.t. Washes and deprotections were performed with 4 mL of DMF (5 × 1 min), 4 mL of DCM (5 × 1 min) and 4 mL of 20% PIP/DMF (5 × 1 min). After the coupling steps, the peptide was deprotected and cleaved from the resin using a treatment with 10 mL of TFA/TIS/H 2 O (95/2.5/2.5) for 3 hrs. The mixture was filtered and added dropwise to a cold mixture MTBE/Hexane (1/1, 30 mL). The precipitate was centrifuged (4500 rpm, 5 min) to afford a yellowish solid which was dissolved in Buffer A/Buffer B (1/1) to achieve complete deprotection and lyophilised. Crude peptides were purified by prep. HPLC as stated in the general information.
ESI -

Synthesis of Fmoc Cys(CH 2 CH 2 P + Me 3 Cl -)-OH (6)
OH
Automatic solid phase peptide synthesis of peptides 11-18
Peptides were assembled using an automatic PTI Tribute Peptide Synthesiser equipped with a UV-monitoring system to monitor the Fmoc removal step. Fmoc-Rink-Amide AM resin (500 mg, 0.115 mmol; 0.23 mmol/g) was used and peptides were assembled on a 0.10 mmol scale (1 eq.). The resin was first washed with 3 mL of DMF (3 × 10 min) followed by the Fmoc deprotection step with 3 mL of 20% PIP/DMF (0.5 minutes, UV monitoring) with subsequent 3 mL DMF washes (5 × 0.5 min). Protected Fmoc-amino acids (4 eq.) were coupled using DIC (4 eq.) and Oxyma pure (4 eq.) in 3 mL of DMF, as coupling system, with 5-minute pre-activation and coupling time of 2 hrs for the phosphonium amino acids and 45 minutes for any other. Washes between couplings and Fmoc deprotection steps were done with 3 mL of DMF (3 × 0.5 min). Final deprotection step was achieved with 3 mL of 20% PIP/DMF (5 × 0.5 min) followed by 3 mL of DMF (3 × 0.5 min) and 3 mL of DCM (3 × 0.5 min). After completion of the synthesis the resin was dried with by a stream of N 2 and the peptide was cleaved and deprotected with 10 mL of TFA/TIS/H 2 O (95/2.5/2.5) for 3 hrs. The mixture was filtered and added dropwise to a cold mixture MTBE/Hexane (1/1, 30 mL). The precipitate was centrifuged (4500 rpm, 5min) to obtain the crude peptides which were dissolved in a mixture Buffer A/Buffer B (1/1) and lyophilised. Crude peptides were purified by prep. HPLC as stated in the general information.
Standard procedure for the synthesis of the fluorescent peptides 1 mL of a stock solution containing 0.86 mg of the BODIPY-Fl 1 and 1.1 mg of EDC·HCl in DMF was added to 5 mg of the purified peptides. The reaction mixture was stirred overnight at r.t. and after this it was diluted by addition of 20 mL of H 2 O and lyophilised. Crude peptides were purified by preparative reverse phase HPLC (0-60%) over 80 minutes. 
ESI -
Synthesis of Peptide 8
Cell Viability Assays
Cell viability was assessed following a protocol with minor modifications 3 . HEK293 cells were used (obtained from ATCC: https://www.lgcstandards-atcc.org/Products/All/CRL-3216.aspx) to carry out this experiment. Cells were seeded in 24 well plates, at a concentration of 1x10 6 cells per well, and incubated overnight. Subsequently, the cell media were changed by media containing the peptides in concentrations of 512, 256 and 128µM and incubated for another 24 hours. Then, the cell media were replaced by fresh media and a solution of 10% (v/v) Alamar Blue was added to each well. Fluorescence readings were obtained after 4 hours at wavelengths of 545nm for excitation and 590 nm for emission. Cells without incubation with any compound were used as positive control and pure media as a blank. All experiments were carried out in triplicate.
Haemolysis assays
The haemolytic activity of the purified peptides was determined using a method that was previously developed by our group with minor modifications 4 . Erythrocytes were isolated from defibrinated horse blood (E&O laboratories Ltd) using centrifugation (1000 x G, 10 minutes). Subsequently the erythrocytes were washed three times with saline solution (0.9% NaCl) prior to use. The erythrocyte pellet was diluted to 5% (v:v) in phosphate buffered saline solution (PBS). Peptide solutions were prepared at a concentration of 512 µM in PBS and aliquots (200 µL/well) were transferred in triplicate to the first column of a sterile 96 well low binding polypropylene microtiter plate (Corning 3879). An aliquot (100 µL/well) was taken from the first column and 2-fold diluted in PBS (100 µL/well). A positive control was prepared to determine 100% haemolysis using Triton X-100 (1% in PBS). PBS was used as a blank. Aliquots (100 µL/well) of the 5% erythrocyte suspension were added to the microtiter plate and incubated for 1 hour at 37 o C. Following incubation, the microtiter plate was centrifuged (1000 x G, 10 min) and 50 µL of supernatant from each well was transferred to a 96-well flat bottom polystyrene microtiter plate (Nunc 269620). The OD at 414 nm was measured in triplicate and used to determine the percentage of haemolysis in comparison to 100% haemolysis (1% Triton X-100). All experiments were carried out in triplicate.
Fluorescent Microscopy
Fluorescent microscopy experiments were carried out based on a standard protocol with time incubation optimisation for the visualisation of the CAP peptides 5 . MCF7 cells were used (obtained from ATCC: https://www.lgcstandards-atcc.org/Products/All/CRL-3216.aspx). The cells were seeded (1.0 × 10 5 ) in 24 wells plates containing 13mm glass cover slips and incubated overnight. After that time, media were changed for 20 µM solutions of the peptides in RPMI-1640 media and incubated for 3 hours, after which the cells were washed with PBS and fixed with a 4% solution of formaldehyde in PBS. The cover slips were then treated with a surfactant solution of PBS/Tween and red fluorescent Rhodamine Phalloidin to stain the cytoskeleton. Cover slips were transferred to slides and mounted with VECTASHIELD mounting media with DAPI to stain the cell's nucleus blue fluorescence. Slides were observed on a Axiovert 200m inverted microscope at 40x. Images were edited on ImageJ ESI -1.51K by the National Institutes of Health. Scale bars represent 10 µm. Experiments were carried out in triplicate and suitable images were selected for Figure 5 . 
CAP 19
Exp
